In the KEYNOTE-158 study, tumor TMB-high status characterized a subgroup of patients with advanced solid tumors who showed a significant tumor remission in response to the anti-PD-1 monoclonal antibody pembrolizumab (Marabelle et al., 2020). This evidence concerns the gene PDCD1 and neoplasm.